10.3389/fnins.2018.00752.s001
Alexander B. Remsik
Alexander B.
Remsik
Keith Dodd
Keith
Dodd
Leroy Williams
Leroy
Williams
Jaclyn Thoma
Jaclyn
Thoma
Tyler Jacobson
Tyler
Jacobson
Janerra D. Allen
Janerra D.
Allen
Hemali Advani
Hemali
Advani
Rosaleena Mohanty
Rosaleena
Mohanty
Matt McMillan
Matt
McMillan
Shruti Rajan
Shruti
Rajan
Matt Walczak
Matt
Walczak
Brittany M. Young
Brittany M.
Young
Zack Nigogosyan
Zack
Nigogosyan
Cameron A. Rivera
Cameron A.
Rivera
Mohsen Mazrooyisebdani
Mohsen
Mazrooyisebdani
Neelima Tellapragada
Neelima
Tellapragada
Leo M. Walton
Leo M.
Walton
Klevest Gjini
Klevest
Gjini
Peter L.E. van Kan
Peter L.E.
van Kan
Theresa J. Kang
Theresa J.
Kang
Justin A. Sattin
Justin A.
Sattin
Veena A. Nair
Veena
A. Nair
Dorothy Farrar Edwards
Dorothy Farrar
Edwards
Justin C. Williams
Justin C.
Williams
Vivek Prabhakaran
Vivek
Prabhakaran
Data_Sheet_1_Behavioral Outcomes Following Brain–Computer Interface Intervention for Upper Extremity Rehabilitation in Stroke: A Randomized Controlled Trial.PDF
Frontiers
2018
brain–computer interface (BCI)
stroke
recovery
rehabilitation
motor function
hemiparesis
upper extremity
2018-11-08 04:06:49
Dataset
https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Behavioral_Outcomes_Following_Brain_Computer_Interface_Intervention_for_Upper_Extremity_Rehabilitation_in_Stroke_A_Randomized_Controlled_Trial_PDF/7312685
<p>Stroke is a leading cause of persistent upper extremity (UE) motor disability in adults. Brain–computer interface (BCI) intervention has demonstrated potential as a motor rehabilitation strategy for stroke survivors. This sub-analysis of ongoing clinical trial (NCT02098265) examines rehabilitative efficacy of this BCI design and seeks to identify stroke participant characteristics associated with behavioral improvement. Stroke participants (n = 21) with UE impairment were assessed using Action Research Arm Test (ARAT) and measures of function. Nine participants completed three assessments during the experimental BCI intervention period and at 1-month follow-up. Twelve other participants first completed three assessments over a parallel time-matched control period and then crossed over into the BCI intervention condition 1-month later. Participants who realized positive change (≥1 point) in total ARAT performance of the stroke affected UE between the first and third assessments of the intervention period were dichotomized as “responders” (<1 = “non-responders”) and similarly analyzed. Of the 14 participants with room for ARAT improvement, 64% (9/14) showed some positive change at completion and approximately 43% (6/14) of the participants had changes of minimal detectable change (MDC = 3 pts) or minimally clinical important difference (MCID = 5.7 points). Participants with room for improvement in the primary outcome measure made significant mean gains in ARAT<sub>total</sub> score at completion (ΔARAT<sub>total</sub> = 2, p = 0.028) and 1-month follow-up (ΔARAT<sub>total</sub> = 3.4, p = 0.0010), controlling for severity, gender, chronicity, and concordance. Secondary outcome measures, SIS<sub>mobility</sub>, SIS<sub>adl</sub>, SIS<sub>strength</sub>, and 9HPT<sub>affected</sub>, also showed significant improvement over time during intervention. Participants in intervention through follow-up showed a significantly increased improvement rate in SIS<sub>strength</sub> compared to controls (p = 0.0117), controlling for severity, chronicity, gender, as well as the individual effects of time and intervention type. Participants who best responded to BCI intervention, as evaluated by ARAT score improvement, showed significantly increased outcome values through completion and follow-up for SIS<sub>mobility</sub> (p = 0.0002, p = 0.002) and SIS<sub>strength</sub> (p = 0.04995, p = 0.0483). These findings may suggest possible secondary outcome measure patterns indicative of increased improvement resulting from this BCI intervention regimen as well as demonstrating primary efficacy of this BCI design for treatment of UE impairment in stroke survivors.</p><p>Clinical Trial Registration:ClinicalTrials.gov, NCT02098265.</p>